🇺🇸 FDA
Patent

US 10300095

AAV mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity

granted A61KA61K35/76A61K35/761

Quick answer

US patent 10300095 (AAV mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity) held by The United States of America as Represented by the Secretary, Dept. of Health and Human Services expires Mon May 23 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary, Dept. of Health and Human Services
Grant date
Tue May 28 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 23 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K35/76, A61K35/761, A61K38/1703, A61K48/005